Mikael Dolsten, M.D., Ph.D., is President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc. He is focused on advancing the company’s pipeline and scientific leadership in small molecule medicines, biotherapeutics and vaccines. He is a member of the Pfizer Executive Leadership Team and co-chairs the company’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.
Dr. Dolsten leads the WRD group at Pfizer, which has responsibility for all research at Pfizer, including development of all compounds through proof of concept (POC), and provides safety, regulatory and clinical operation support to the entire R&D pipeline.
The WRD group contains all Pfizer research units, including Cardiovascular & Metabolic Disease, Neuroscience, Pain, Oncology, Inflammation & Remodeling, Immunoscience, Vaccines and Rare Disease, as well as the Centers for Therapeutic Innovation (CTI) and the biotech unit Rinat. Dr. Dolsten also has worldwide responsibility for Pfizer’s groups in safety, regulatory and development operations, and external R&D innovation in addition to science-based teams in pharmaceutical sciences, drug safety R&D and large and small molecule discovery and development.
Prior to joining Pfizer in 2009, Dr. Dolsten was President of Wyeth Research where he led scientists across the US, Europe and Asia. Before joining Wyeth, he served as Executive Vice President at Boehringer Ingelheim, where he was responsible for R&D in the US, Canada, Germany, Italy, Austria and Japan. His earlier career as a pharmaceutical research leader included positions with AstraZeneca, Pharmacia and Upjohn.
Dr. Dolsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund.
Dr. Dolsten is a fellow of the New York Academy of Medicine, a governor of the New York Academy of Sciences, and a member of the Board of Trustees of the New York Hall of Science. A member of the Biomedical Advisory Council of The Pharmaceutical Research and Manufacturers of America (PhRMA), Dr. Dolsten also serves on the PhRMA Foundation Board of Directors, and is a member of the Government University Industry Research Roundtable (GUIRR). Dr. Dolsten is a named inventor on several patents and has published approximately 150 articles in international journals, with particular contributions in areas such as molecular cell biology, immunology and oncology.